Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Figure 1
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Open Access | 10.1172/JCI180583

Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis

Dennis G. Moledina, Wassim Obeid, Rex N. Smith, Ivy Rosales, Meghan E. Sise, Gilbert Moeckel, Michael Kashgarian, Michael Kuperman, Kirk N. Campbell, Sean Lefferts, Kristin Meliambro, Markus Bitzer, Mark A. Perazella, Randy L. Luciano, Jordan S. Pober, Lloyd G. Cantley, Robert B. Colvin, F. Perry Wilson, and Chirag R. Parikh

Find articles by Moledina, D. in: PubMed | Google Scholar |

Find articles by Obeid, W. in: PubMed | Google Scholar |

Find articles by Smith, R. in: PubMed | Google Scholar

Find articles by Rosales, I. in: PubMed | Google Scholar |

Find articles by Sise, M. in: PubMed | Google Scholar |

Find articles by Moeckel, G. in: PubMed | Google Scholar |

Find articles by Kashgarian, M. in: PubMed | Google Scholar |

Find articles by Kuperman, M. in: PubMed | Google Scholar

Find articles by Campbell, K. in: PubMed | Google Scholar

Find articles by Lefferts, S. in: PubMed | Google Scholar

Find articles by Meliambro, K. in: PubMed | Google Scholar

Find articles by Bitzer, M. in: PubMed | Google Scholar |

Find articles by Perazella, M. in: PubMed | Google Scholar

Find articles by Luciano, R. in: PubMed | Google Scholar

Find articles by Pober, J. in: PubMed | Google Scholar |

Find articles by Cantley, L. in: PubMed | Google Scholar |

Find articles by Colvin, R. in: PubMed | Google Scholar |

Find articles by Wilson, F. in: PubMed | Google Scholar

Find articles by Parikh, C. in: PubMed | Google Scholar |

Published March 15, 2024 - More info

Published in Volume 134, Issue 6 on March 15, 2024
J Clin Invest. 2024;134(6):e180583. https://doi.org/10.1172/JCI180583.
© 2024 Moledina et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published March 15, 2024 - Version history
View PDF

Related article:

Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Dennis G. Moledina, … , F. Perry Wilson, Chirag R. Parikh
Dennis G. Moledina, … , F. Perry Wilson, Chirag R. Parikh
Clinical Research and Public Health Nephrology

Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis

  • Text
  • PDF
Abstract

Background Acute tubulointerstitial nephritis (AIN) is one of the few causes of acute kidney injury with diagnosis-specific treatment options. However, due to the need to obtain a kidney biopsy for histological confirmation, AIN diagnosis can be delayed, missed, or incorrectly assumed. Here, we identify and validate urinary CXCL9, an IFN-γ-induced chemokine involved in lymphocyte chemotaxis, as a diagnostic biomarker for AIN.Methods In a prospectively enrolled cohort with pathologist-adjudicated histological diagnoses, termed the discovery cohort, we tested the association of 180 immune proteins measured by a proximity extension assay with AIN and validated the top protein, CXCL9, using sandwich immunoassay. We externally validated these findings in 2 cohorts with biopsy-confirmed diagnoses, termed the validation cohorts, and examined mRNA expression differences in kidney tissue from patients with AIN and individuals in the control group.Results In a proximity extension assay, urinary CXCL9 was 7.6-fold higher in patients with AIN than in individuals in the control group (P = 1.23 × 10–5). Urinary CXCL9 measured by sandwich immunoassay was associated with AIN in the discovery cohort (n = 204; 15% AIN) independently of currently available clinical tests for AIN (adjusted odds ratio for highest versus lowest quartile: 6.0 [1.8–20]). Similar findings were noted in external validation cohorts, where CXCL9 had an AUC of 0.94 (0.86–1.00) for AIN diagnosis. CXCL9 mRNA expression was 3.9-fold higher in kidney tissue from patients with AIN (n = 19) compared with individuals in the control group (n = 52; P = 5.8 × 10–6).Conclusion We identified CXCL9 as a diagnostic biomarker for AIN using proximity extension urine proteomics, confirmed this association using sandwich immunoassays in discovery and external validation cohorts, and observed higher expression of this protein in kidney biopsies from patients with AIN.Funding This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awards K23DK117065 (DGM), K08DK113281 (KM), R01DK128087 (DGM), R01DK126815 (DGM and LGC), R01DK126477 (KNC), UH3DK114866 (CRP, DGM, and FPW), R01DK130839 (MES), and P30DK079310 (the Yale O’Brien Center). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Authors

Dennis G. Moledina, Wassim Obeid, Rex N. Smith, Ivy Rosales, Meghan E. Sise, Gilbert Moeckel, Michael Kashgarian, Michael Kuperman, Kirk N. Campbell, Sean Lefferts, Kristin Meliambro, Markus Bitzer, Mark A. Perazella, Randy L. Luciano, Jordan S. Pober, Lloyd G. Cantley, Robert B. Colvin, F. Perry Wilson, Chirag R. Parikh

×

Original citation: J Clin Invest. 2023;133(13):e168950. https://doi.org/10.1172/JCI168950

Citation for this corrigendum: J Clin Invest. 2024;134(6):e180583. https://doi.org/10.1172/JCI180583

In the abstract and the legend for Figure 1, the descriptions of the Olink Proteomics assays utilized were incorrect. The correct descriptions appear below. The HTML and PDF versions of the article have been updated online.

Abstract

Methods. In a prospectively enrolled cohort with pathologist-adjudicated histological diagnoses, termed the discovery cohort, we tested the association of 180 immune proteins measured by a proximity extension assay with AIN and validated the top protein, CXCL9, using sandwich immunoassay.

Results. In a proximity extension assay, urinary CXCL9 was 7.6-fold higher in patients with AIN than in individuals in the control group (P = 1.23 × 10–5).

Conclusion. We identified CXCL9 as a diagnostic biomarker for AIN using proximity extension urine proteomics, confirmed this association using sandwich immunoassays in discovery and external validation cohorts, and observed higher expression of this protein in kidney biopsies from patients with AIN.

Figure 1

Volcano plot demonstrating associations of proximity extension measurement of urine proteins with acute interstitial nephritis diagnosis.

The authors regret the errors.

Footnotes

See the related article at Identification and validation of urine CXCL9 as a biomarker for diagnosis of acute interstitial nephritis.

Version history
  • Version 1 (March 15, 2024): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Figure 1
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts